Cargando…

MON-LB029 The Influence of SGLT-2 Inhibitors and Other Glucose-Lowering Therapies on All-Cause Mortality Risk and Cardiovascular Outcomes in Older Patients with Newly Treated Type 2 Diabetes: A Population-Based Cohort Study

Background: SGLT-2 inhibitors (SGLT-2i) have been associated with decreased all-cause mortality and cardiovascular (CV) morbidity in patients with type 2 diabetes (T2DM) and established CV disease in randomized trials. The objective of this study was to evaluate exposure time to SGLT-2i and other di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Doyle, Mary-Anne, Arnaout, Amel, Malcolm, Janine, Lochnan, Heather, Keely, Erin, van Walraven, Carl
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2019
Materias:	Diabetes Mellitus and Glucose Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551125/ http://dx.doi.org/10.1210/js.2019-MON-LB029

Ejemplares similares

MON-LB123 Diagnosis and Management of Euglycemic DKA in the Setting of SGLT2 Inhibitor Use and Prostate Abscess
por: Rameshkumar, Naveen Sundar
Publicado: (2020)

SAT-LB029 Patient Participation Is Determined by Referral Source in an Intensive Diabetes Management Program
por: Blase, Bryan, et al.
Publicado: (2019)

MON-LB122 Psychiatric Medication Induced Diabetes Mellitus
por: Khanal, Bishal, et al.
Publicado: (2020)

SUN-LB029 A Case of Gestational Diabetes with Diabetic Ketoacidosis, Insulin Injection Site Reaction and Anti Insulin Antibodies in Pregnancy
por: Hakimian, Stephanie, et al.
Publicado: (2019)

MON-690 Euglycemic Diabetic Ketoacidosis Associated with SGLT-2 Inhibitors- an Under-recognized Diagnosis
por: Chhabra, Sarah, et al.
Publicado: (2020)

MON-LB024 Episodic Hypoglycemia in Non-Diabetics: Differentiating Distressing from Deadly
por: Windham, Mary, et al.
Publicado: (2019)

MON-LB031 Higher Insulin Degrading Enzyme Levels in Subjects with Metabolic Syndrome
por: Sofer, Yael, et al.
Publicado: (2019)

MON-LB127 Pulmonary Embolism in the Setting of Diabetic Ketoacidosis. an Under-Recognized Complication
por: Ahmed, Adeel Jabran, et al.
Publicado: (2020)

MON-LB119 Euglycemic Diabetic Ketoacidosis in a Patient on Canagliflozin Presenting With Hypoglycemia
por: Inkollu, Sindhura, et al.
Publicado: (2020)

MON-LB034 Acanthosis Nigricans: A Predictor of Developing Type 2 Diabetes in a High Risk Population?
por: Davison, Belinda, et al.
Publicado: (2019)

MON-694 EDKA and MALA in the Setting of Severe Heart Failure and Acute Renal Failure, Due to SGLT2-i
por: Heckart, Jonathan Calvin, et al.
Publicado: (2020)

MON-LB026 Critical Illness Associated Fatal Hypoglycemia in a Non-Diabetic Male
por: Toor, Amit, et al.
Publicado: (2019)

MON-LB109 Transcutaneous Magnetic Stimulation: A Novel Treatment of Diabetic Peripheral Neuropathy
por: Satyarengga, Medha, et al.
Publicado: (2020)

MON-LB112 Socioeconomic Status, Literacy, and Sex Differences in the Progression of Retinopathy in Patients With Type 2 Diabetes in Tokyo, Japan
por: Emoto, Naoya, et al.
Publicado: (2020)

MON-LB028 Comparing Cardiovascular Effects of GLP-1 Agonists in a Real World Setting
por: Wallia, Amisha, et al.
Publicado: (2019)

MON-LB025 An Artificially Low HbA1c as a Result of Dapsone Therapy
por: George, Robert, et al.
Publicado: (2019)

MON-LB128 Phosphoinositide 3-Kinase (PI3K) Inhibitor Induced Hyperglycemia With Alpelisib
por: Barsukova, Yuliya, et al.
Publicado: (2020)

MON-LB111 Evaluation of Mixed Meal Test on the Diagnosis of Hyperinsulinemic Hypoglycemia After Bariatric Surgery
por: Asato, Marilia Tomiyoshi, et al.
Publicado: (2020)

MON-LB125 Dka From a Ketogenic Diet and Intermittent Fasting or Ketosis-Prone Diabetes?
por: Athonvarangkul, Diana, et al.
Publicado: (2020)

MON-LB114 CGM in Cystic Fibrosis Patients to Predict Cystic Fibrosis-Related Diabetes Onset
por: Mei Hsia Pu, Mariana Zorron, et al.
Publicado: (2020)

MON-LB124 Euglycemic Diabetic Ketoacidosis on Initiation of Ertugliflozin in a Patient With Type 2 Diabetes Mellitus Precipitated by a Ketogenic Diet
por: Richstein, Ryan, et al.
Publicado: (2020)

MON-LB030 Muscle Mitochondrial Oxidative Phosphorylation Capacity and Whole Body Glucose Metabolism in Friedreich's Ataxia
por: Nguyen, Sara, et al.
Publicado: (2019)

MON-LB121 New Onset Insulin Dependent Diabetes Mellitus Secondary to Treatment With Immune Checkpoint Inhibitor
por: Bitat, Syed Rabha
Publicado: (2020)

MON-LB115 Ready-To-Use Glucagon for the Prevention of Exercise-Induced Hypoglycemia in a Clinical Research Setting
por: Aronson, Ronnie, et al.
Publicado: (2020)

MON-LB120 MODY3 With Insulin Coding Gene Mutation and Craniofacial Microsomia: A Case Report
por: Cao, Chenxiang, et al.
Publicado: (2020)

MON-LB116 FGF-21 Is A Reliable Marker Of Insulin Resistance Before The Occurrence Of Glucose Intolerance
por: sawah, ahmed, et al.
Publicado: (2020)

SUN-687 MODY-14: A Rare Cause of Inherited Diabetes
por: Epp, Riley, et al.
Publicado: (2020)

MON-LB110 A Phase 2 Evaluation of a Ready-To-Use Liquid Stable Continuous Subcutaneous Glucagon Infusion for the Treatment of Hypoglycemia Associated Autonomic Failure
por: Pettus, Jeremy H, et al.
Publicado: (2020)

MON-LB027 Clinical Case of Using GH-Method: Math-Physical Medicine to Control Type 2 Diabetes Patient via Both Lifestyle Management and Effective Medication
por: Hsu, Gerald, et al.
Publicado: (2019)

Euglycemic Diabetic Ketoacidosis With SGLT-2 Inhibitor
por: Manas, F N U, et al.
Publicado: (2021)

Euglycemic DKA Associated With SGLT2 Inhibitors
por: TakallooBakhtiari, Asieh, et al.
Publicado: (2021)

SAT-LB027 Does Diabetes Education Influence Glycosylated Hemoglobin?
por: Bhargava, Pooja, et al.
Publicado: (2019)

MON-LB033 Unleashing the Anti-Inflammatory Potential of Treg Cells Against Type I Diabetes Using Advanced Chimeric Antigen Receptor Technology
por: Imam, Shahnawaz, et al.
Publicado: (2019)

MON-LB113 Insulin Resistance in Type 1 Diabetes Managed With Metformin (INTIMET): Rationale and Study Design of a Randomised Placebo-Controlled Trial
por: Snaith, Jennifer R, et al.
Publicado: (2020)

MON-LB126 A Benign and Favorable Diagnosis: Glycogen Hepatopathy Causing Transient Transaminitis During Diabetic Ketoacidosis in Type 1 Diabetes Mellitus
por: Yau, Alice, et al.
Publicado: (2020)

Precipitation of Euglycemic DKA (euDKA) From the Initiation of SGLT2 Inhibitor (SGLT2i) and 0-Carb Diet Inpatient
por: Popli, Rakesh, et al.
Publicado: (2021)

MON-LB117 Differences in Metabolic Control, Treatment and Associated Complications in Patients Living With Type 1 Diabetes Receiving Private or Public Health Care in Mexico
por: Faradji, Raquel N, et al.
Publicado: (2020)

SAT-LB110 Sulfonylurea-Induced Hypoglycemia: To Use Octreotide or Not
por: Romeu, Jose, et al.
Publicado: (2020)

Current Utilization Trends of SGLT-2 Inhibitors in Type 2 Diabetics With Heart Failure
por: Dhillon, Puneet, et al.
Publicado: (2021)

Euglycemic DKA in Patients on SGLT2 Inhibitor and Potentially Ketotic State
por: Khalifa, Maram, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_17k8ee3j3i6elf3st55t78pmpi